PT - JOURNAL ARTICLE AU - Anna Deal AU - Alison F Crawshaw AU - Jessica Carter AU - Felicity Knights AU - Michiyo Iwami AU - Mohammad Darwish AU - Rifat Hossain AU - Palmira Immordino AU - Kanokporn Kaojaroen AU - Santino Severoni AU - Sally Hargreaves TI - Defining drivers of under-immunisation and vaccine hesitancy in refugee and migrant populations globally to support strategies to strengthen vaccine uptake for COVID-19: a rapid review AID - 10.1101/2023.03.20.23287477 DP - 2023 Jan 01 TA - medRxiv PG - 2023.03.20.23287477 4099 - http://medrxiv.org/content/early/2023/03/20/2023.03.20.23287477.short 4100 - http://medrxiv.org/content/early/2023/03/20/2023.03.20.23287477.full AB - Background Some refugee and migrant populations have been disproportionately impacted by the COVID-19 pandemic, yet evidence suggests lower uptake of COVID-19 vaccines. They are also an under-immunised group for many routine vaccines. We did a rapid review to explore drivers of under-immunisation and vaccine hesitancy among refugee and migrant populations globally to define strategies to strengthen both COVID-19 and routine vaccination uptake.Methods We collected global literature (01/01/2010 - 05/05/2022) pertaining to drivers of under-immunisation and vaccine hesitancy in refugees and migrants, incorporating all vaccines. We searched MEDLINE, Embase, Global Health PsycINFO and the WHO’s ‘Global Research on COVID-19’ database and grey literature. Qualitative data were analysed thematically to identify drivers of under-immunisation and vaccine hesitancy, then categorised using the ‘Increasing Vaccination Model’.Results 63 papers were included in this review, reporting data on diverse population groups, including refugees, asylum seekers, labour and undocumented migrants from 22 countries, with six papers reporting on a regional or global scale. Drivers of under-immunisation and vaccine hesitancy pertaining to a wide range of vaccines were covered, including COVID-19 (n=27), HPV (13), measles or MMR (3), influenza (3), tetanus (1), and vaccination in general. We found a range of factors driving under-immunisation and hesitancy in refugee and migrant groups, including unique awareness and access factors that need to be better considered in policy and service delivery. Acceptability of vaccination was often deeply rooted in social and historical context and influenced by personal risk perception.Conclusions These findings hold direct relevance to current efforts to ensure high levels of global immunisation coverage, key to which is to ensure marginalised refugees and migrant populations are included in national vaccination plans of low-middle- and high-income countries. We found a stark lack of research from low- and middle-income and humanitarian contexts on vaccination in mobile groups, a situation that needs to be urgently rectified to ensure high coverage for COVID-19 and routine vaccinations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Department of Foreign Affairs, Trade and Development (DFATD), Canada. AD is funded by the Medical Research Council (MRC/N013638/1). SH is funded by the National Institute for Health Research (NIHR Advanced Fellowship 300072), the Academy of Medical Sciences (SBF005\1111) and the La Caixa Foundation, and acknowledges funding from the MRC and WHO. All authors declare no competing interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript